Dec 01, 2021 / 01:30PM GMT
Operator
Good morning, everyone, and thank you for standing by and welcome to the VBI Vaccines conference call. (Operator Instructions) As a reminder, this conference call will be recorded.
I'd now like to turn the conference over to Nicole Anderson, Director of Corporate Communications and Investor Relations. Please go ahead.
Nicole Anderson - VBI Vaccines Inc. - Director of Corporate Communications & IR
Good morning. Thank you all for joining us on the call today as we announce the U.S. FDA approval of PreHevbrio, our 3-antigen hepatitis B vaccine now approved for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults aged 18 years and older.
We issued a press release sharing this news earlier this morning. Joining me on the call from VBI is Jeff Baxter, President and CEO.
Before we begin, I would like to remind you that this call will contain certain forward-looking statements. Specifically, I would like to remind everyone that all statements other than statements of historical fact included in this
VBI Vaccines Inc to Discuss on FDA Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults - Corporate Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot